Compare CFBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFBK | SGHT |
|---|---|---|
| Founded | 1892 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 187.4M |
| IPO Year | 2005 | 2021 |
| Metric | CFBK | SGHT |
|---|---|---|
| Price | $27.80 | $3.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $29.00 | $9.08 |
| AVG Volume (30 Days) | 41.7K | ★ 384.0K |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 30.58 | 28.16 |
| EPS | ★ 2.69 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $32.28 | $11.81 |
| Revenue Next Year | N/A | $10.62 |
| P/E Ratio | $10.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.22 | $2.03 |
| 52 Week High | $34.34 | $9.24 |
| Indicator | CFBK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 37.20 |
| Support Level | $23.49 | $3.29 |
| Resistance Level | $29.95 | $3.76 |
| Average True Range (ATR) | 0.69 | 0.20 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 33.75 | 36.43 |
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.